Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Dec 2024 value amounting to $1.3 million.

  • Madrigal Pharmaceuticals' Gains from Investment Securities was N/A to $162,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $3.4 million, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2024, which is 18.30% down from last year.
  • According to the latest figures from FY2024, Madrigal Pharmaceuticals' Gains from Investment Securities is $1.3 million, which was down 18.30% from $1.6 million recorded in FY2023.
  • Madrigal Pharmaceuticals' 5-year Gains from Investment Securities high stood at $1.6 million for FY2023, and its period low was $376,000 during FY2021.
  • In the last 3 years, Madrigal Pharmaceuticals' Gains from Investment Securities had a median value of $1.3 million in 2024 and averaged $1.2 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 49.89% in 2020, then surged by 179.25% in 2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $451,000 in 2020, then fell by 16.63% to $376,000 in 2021, then spiked by 55.05% to $583,000 in 2022, then skyrocketed by 179.25% to $1.6 million in 2023, then declined by 18.30% to $1.3 million in 2024.